Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response.
about
Therapeutic options in post-transplant lymphoproliferative disorders.A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies.Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia.Thymus transplantation for complete DiGeorge syndrome: European experience.A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumorsDetection of Epstein-Barr virus genomes in peripheral blood B cells from solid-organ transplant recipients by fluorescence in situ hybridization.Herpesvirus infections in organ transplant recipientsReduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★).Molecular parameters for precise diagnosis of asymptomatic Epstein-Barr virus reactivation in healthy carriersSimultaneous quantification of Epstein-Barr virus, cytomegalovirus, and human herpesvirus 6 DNA in samples from transplant recipients by multiplex real-time PCR assay.Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseasesEffects of chemotherapy in AIDS-associated non-Hodgkin's lymphoma on Kaposi's sarcoma herpesvirus DNA in bloodSurface immunoglobulin-deficient Epstein-Barr virus-infected B cells in the peripheral blood of pediatric solid-organ transplant recipients.Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.Comparative Evaluation of Four Real-Time PCR Methods for the Quantitative Detection of Epstein-Barr Virus from Whole Blood Specimens.Lytic EBV infection investigated by detection of Soluble Epstein-Barr virus ZEBRA in the serum of patients with PTLD.Drug Modulators of B Cell Signaling Pathways and Epstein-Barr Virus Lytic Activation.Evidence for both lytic replication and tightly regulated human herpesvirus 8 latency in circulating mononuclear cells, with virus loads frequently below common thresholds of detection.Healthy rabbits are susceptible to Epstein-Barr virus infection and infected cells proliferate in immunosuppressed animals.The efficacy of EBER in situ hybridization (ISH) stain in PTLD (malignant diffuse large B-cell lymphoma) about 4 years after ABO-incompatible kidney transplantation: a case report
P2860
Q30455714-547F708F-133C-4442-871D-A21D90EFA513Q30496656-4B1996AE-BA5D-4736-A232-D8A6C8F9F600Q33218405-D8079AF8-2949-432F-81E4-CCCE36509F2FQ33440911-366743C4-EBC6-4C14-B9D5-40C33D19B7DFQ33752772-DC8CB2B1-16A6-4123-8CE0-5552448A721CQ33962280-68E2E4BC-041A-43A9-A2F3-6F67D6AC1F89Q34579836-77AE00D2-0657-4533-A1C2-9FB3024CEE0AQ34815054-B76E62DE-77CF-4CC5-BFFE-94A2C539998DQ34948319-1977035D-2CF6-4247-BBDD-FF458D1CCEA2Q35784500-27FAA16D-D96D-48DC-9132-1C3D4ABC5DD4Q35986609-F7554A4D-B7CF-4B38-9267-9A37BC002F7BQ36825808-F745255B-166E-4CE2-B324-427072B320BAQ37198986-172D1AC7-6F14-4E71-B784-597ADA5E848DQ37702857-A27F8C05-8D21-4E15-9214-5A26400C4D41Q37726624-285A6933-6412-44CE-8981-E282F802C014Q39784991-561371A0-B22D-4114-80D8-7759CDD742F1Q40056807-89DDA690-CB29-4A23-BF24-1935FBBDEB5AQ40178497-CBC5587F-AC8D-486D-A6FE-01912A295FADQ40213186-10900AB0-43C3-4F67-8506-1E346CC219B2Q41902982-0D51D6CF-932D-4FFB-B9B0-FE7CD4586870Q42182928-D1BAD16C-AAD5-40BE-8AF4-BE47E53CE59F
P2860
Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Characterization of Epstein-Ba ...... not predict clinical response.
@en
Characterization of Epstein-Ba ...... not predict clinical response.
@nl
type
label
Characterization of Epstein-Ba ...... not predict clinical response.
@en
Characterization of Epstein-Ba ...... not predict clinical response.
@nl
prefLabel
Characterization of Epstein-Ba ...... not predict clinical response.
@en
Characterization of Epstein-Ba ...... not predict clinical response.
@nl
P2093
P1433
P1476
Characterization of Epstein-Ba ...... not predict clinical response
@en
P2093
Ambinder RF
Caligiuri MA
Piantadosi S
P304
P407
P577
2000-12-01T00:00:00Z